Evaluating the role of CDK4/6 inhibition on STAT3 activation in a transgenic mouse model of HER2-positive breast cancer

被引：0
|
作者：
Adesoye, Taiwo
Luo, Linjie
Bui, Tuyen
Kim, Serena
Wingate, Hannah
Tripathy, Debu
Hunt, Kelly
Keyomarsi, Khandan
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO1-25-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO1-25-08
引用
收藏
页数：3
相关论文
共 50 条
  • [21] CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects
    Wekking, Demi
    Leoni, Vera Piera
    Lambertini, Matteo
    Dessi, Mariele
    Pretta, Andrea
    Cadoni, Andrea
    Atzori, Luigi
    Scartozzi, Mario
    Solinas, Cinzia
    CYTOKINE & GROWTH FACTOR REVIEWS, 2024, 75 : 57 - 64
  • [22] Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition
    Schedin, Troy B.
    Borges, Virginia F.
    Shagisultanova, Elena
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2018, 2018
  • [23] STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer
    Wang, Lei
    Wang, Quanren
    Gao, Mingzhao
    Fu, Li
    Li, Yun
    Quan, Haitian
    Lou, Liguang
    CANCER SCIENCE, 2018, 109 (10): : 3305 - 3315
  • [24] Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)
    Laguna, J. C.
    Braso-Maristany, F.
    Pascual, T.
    Rodriguez Hernandez, A.
    Chic, N.
    Schettini, F.
    Sanfeliu Torres, E.
    Gonzalez-Farre, B.
    Martinez, D.
    Galvan, P.
    Diez-Guardia, V.
    Adamo, B.
    Vidal, M.
    Guillen Sacoto, M. C.
    Moreno, R.
    Prat, A.
    Munoz, M.
    Martinez-Saez, O.
    ANNALS OF ONCOLOGY, 2021, 32 : S69 - S70
  • [25] Niclosamide reverses cisplatin resistance by inhibiting Bcl-2 and Stat3 in HER2-positive breast cancer
    Liu, Junjun
    CANCER RESEARCH, 2021, 81 (04)
  • [26] Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer
    Seachrist, Darcie D.
    Sizemore, Steven T.
    Johnson, Emhonta
    Abdul-Karim, Fadi W.
    Bonk, Kristen L. Weber
    Keri, Ruth A.
    BREAST CANCER RESEARCH, 2017, 19
  • [27] Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer
    Darcie D. Seachrist
    Steven T. Sizemore
    Emhonta Johnson
    Fadi W. Abdul-Karim
    Kristen L. Weber Bonk
    Ruth A. Keri
    Breast Cancer Research, 19
  • [28] Predicting sensitivity to CDK4/6 inhibition in ER+/HER2-breast cancer cell lines
    Bathurst, Lauren
    Liao, Linda
    Crozier, Cheryl
    Bayani, Jane
    Bartlett, John
    Spears, Melanie
    CANCER RESEARCH, 2020, 80 (04)
  • [29] Does HER2 Affect CDK4/6 Pathway Activity in Breast Cancer?
    Cui, Xiaoyan
    Sinclair, William
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 92 - 94
  • [30] CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2+ Breast Cancer
    Malumbres, Marcos
    CANCER CELL, 2016, 29 (03) : 243 - 244
12345